teprenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists	2596	6809-52-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tetraprenylacetone tetraprenyl acetone teprenone geranylgeranylacetone selbex	; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers Molecular weight: 330.56 Formula: C23H38O CLOGP: 7.92 LIPINSKI: None HAC: 1 HDO: 0 TPSA: 17.07 ALOGS: -5.32 ROTB: 12

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tetraprenylacetone
tetraprenyl acetone
teprenone
geranylgeranylacetone
selbex

; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers

Molecular weight: 330.56
Formula: C23H38O
CLOGP: 7.92
LIPINSKI: None
HAC: 1
HDO: 0
TPSA: 17.07
ALOGS: -5.32
ROTB: 12

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	75.11	25.08	35	2674	37107	63449206
Interstitial lung disease	66.19	25.08	38	2671	61870	63424443
Platelet count decreased	52.98	25.08	42	2667	116080	63370233
Renal impairment	46.94	25.08	35	2674	88320	63397993
Anaemia	40.76	25.08	56	2653	293374	63192939
Upper respiratory tract inflammation	40.02	25.08	11	2698	2512	63483801
White blood cell count decreased	38.68	25.08	38	2671	139066	63347247
Cerebral haemorrhage	35.87	25.08	20	2689	30709	63455604
Osteonecrosis of jaw	28.29	25.08	18	2691	35105	63451208
Cardiac failure	25.96	25.08	25	2684	89117	63397196
Aspartate aminotransferase increased	25.69	25.08	25	2684	90252	63396061

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	54.28	23.80	51	2160	119666	34835054
Anaemia	42.26	23.80	62	2149	233273	34721447
Hepatic function abnormal	41.69	23.80	29	2182	44334	34910386
Liver disorder	29.65	23.80	21	2190	32976	34921744
Decreased appetite	26.88	23.80	42	2169	166350	34788370
Neutrophil count decreased	25.45	23.80	23	2188	51081	34903639
C-reactive protein increased	24.33	23.80	23	2188	54075	34900645
White blood cell count decreased	24.27	23.80	30	2181	95415	34859305

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	103.22	21.74	63	5272	73044	79666009
Platelet count decreased	97.56	21.74	90	5245	194574	79544479
Anaemia	70.87	21.74	115	5220	444900	79294153
Interstitial lung disease	68.16	21.74	58	5277	112542	79626511
White blood cell count decreased	57.85	21.74	67	5268	188221	79550832
Renal impairment	55.05	21.74	60	5275	157723	79581330
Upper respiratory tract inflammation	49.61	21.74	16	5319	4019	79735034
Liver disorder	45.22	21.74	38	5297	72379	79666674
Hyperuricaemia	42.26	21.74	19	5316	11780	79727273
Neutrophil count decreased	38.57	21.74	39	5296	93920	79645133
Cerebral haemorrhage	37.52	21.74	31	5304	57642	79681411
Enterocolitis	35.56	21.74	18	5317	14494	79724559
Drug eruption	33.67	21.74	26	5309	43909	79695144
Drug ineffective	32.48	21.74	16	5319	1080897	78658156
Fatigue	32.39	21.74	11	5324	929716	78809337
Pyrexia	32.24	21.74	109	5226	678600	79060453
Disseminated intravascular coagulation	31.44	21.74	23	5312	35819	79703234
Cerebral infarction	30.65	21.74	25	5310	45651	79693402
Erythema multiforme	29.54	21.74	17	5318	17634	79721419
Decreased appetite	28.00	21.74	67	5268	342351	79396702
Malignant neoplasm progression	26.95	21.74	39	5296	135951	79603102
Gamma-glutamyltransferase increased	26.75	21.74	25	5310	54655	79684398
Osteonecrosis of jaw	25.57	21.74	22	5313	43204	79695849
C-reactive protein increased	25.56	21.74	37	5298	128990	79610063
Gastric ulcer haemorrhage	24.49	21.74	12	5323	9015	79730038
Pneumonia	22.95	21.74	96	5239	660150	79078903
Alanine aminotransferase increased	21.75	21.74	39	5296	162531	79576522

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BX15	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D005765	Gastrointestinal Agents
CHEBI has role	CHEBI:49201	anti-ulcer drugs
CHEBI has role	CHEBI:62868	hepatoprotective agents
CHEBI has role	CHEBI:63726	neuroprotective agents
CHEBI has role	CHEBI:76595	nephroprotective agents
CHEBI has role	CHEBI:77307	cardioprotective agents
CHEBI has role	CHEBI:78606	heat shock protein 70 inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01827	KEGG_DRUG
3796-63-2	SECONDARY_CAS_RN
C0061231	UMLSCUI
CHEBI:31649	CHEBI
CHEMBL79686	ChEMBL_ID
CHEMBL3989432	ChEMBL_ID
DB15955	DRUGBANK_ID
C031049	MESH_SUPPLEMENTAL_RECORD_UI
5282199	PUBCHEM_CID
5412	INN_ID
S8S8451A4O	UNII
1362746	RXNORM

Pharmaceutical products:

None